Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Systematic Review
Authors: Parker, Ashleigh F.a; b | Ohlhauser, Lisaa; b | Scarapicchia, Vanessaa; b | Smart, Colette M.a; b | Szoeke, Cassandrac | Gawryluk, Jodie R.a; b; d; *
Affiliations: [a] Department of Psychology, University of Victoria, BC, Canada | [b] Institute on Aging and Lifelong Health, University of Victoria, BC, Canada | [c] Department of Medicine, University of Melbourne, Melbourne, Australia | [d] Division of Medical Sciences, University of Victoria, BC, Canada
Correspondence: [*] Correspondence to: Jodie Gawryluk, Department of Psychology, P. O. Box 1700 STN CSC, University of Victoria, Victoria, British Columbia, V8W 2Y2, Canada. Tel.: +1 250 721 7549; E-mail: gawryluk@uvic.ca.
Abstract: Background:Individuals with subjective cognitive decline (SCD) are hypothesized to be the earliest along the cognitive continuum between healthy aging and Alzheimer’s disease (AD), although more research is needed on this topic. Given that treatment approaches may be most effective pre-clinically, a primary objective of emerging research is to identify biological markers of SCD using neuroimaging methods. Objective:The current review aimed to comprehensively present the neuroimaging studies on SCD to date. Methods:PubMed and PsycINFO databases were searched for neuroimaging studies of individuals with SCD. Quality assessments were completed using the Appraisal tool for Cross-Sectional Studies. Results:In total, 62 neuroimaging studies investigating differences between participants with SCD and healthy controls were identified. Specifically, the number of studies were as follows: 36 MRI, 6 PET, 8 MRI/PET, 4 EEG, 7 MEG, and 1 SPECT. Across neuroimaging modalities, 48 of the 62 included studies revealed significant differences in brain structure and/or function between groups. Conclusion:Neuroimaging methods can identify differences between healthy controls and individuals with SCD. However, inconsistent results were found within and between neuroimaging modalities. Discrepancies across studies may be best accounted for by methodological differences, notably variable criteria for SCD, and differences in participant characteristics and risk factors for AD. Clinic based recruitment and cross-sectional study design were common and may bias the literature. Future neuroimaging investigations of SCD should consistently incorporate the standardized research criteria for SCD (as recommended by the SCD-Initiative), include more details of their SCD sample and their symptoms, and examine groups longitudinally.
Keywords: Healthy controls, neuroimaging, subjective cognitive decline, systematic review
DOI: 10.3233/JAD-215249
Journal: Journal of Alzheimer's Disease, vol. 86, no. 4, pp. 1545-1567, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl